WAVE Life Sciences (NASDAQ: WVE) saw its stock price plummet 5.36% in pre-market trading on Thursday following the release of its first-quarter 2025 financial results. The biotechnology company reported earnings that fell short of analysts' expectations, triggering a sell-off among investors.

The company reported a quarterly loss of $0.29 per share, missing the consensus estimate of a $0.26 loss. This represents a 20.83% increase in losses compared to the same quarter last year. Revenue also disappointed, coming in at $9.18 million, significantly below the analyst forecast of $12.23 million and marking a 26.82% decrease from the previous year.

Further adding to investor concerns, WAVE Life Sciences reported a net loss of $46.878 million, worse than the estimated $43.2 million loss. The company's income from operations also fell short, posting a loss of $49.804 million against expectations of a $45.9 million loss. Despite these challenges, the company maintains a strong cash position of $243.1 million, which it expects will fund operations into 2027. However, this long-term outlook was not enough to offset the immediate disappointment in quarterly results, leading to the sharp decline in stock price.